{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:34:39Z","timestamp":1791441279792,"version":"4.3.3"},"reference-count":120,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mucopolysaccharidoses (MPSs) are multiorgan devastating diseases for which hematopoietic cell transplantation (HCT) and, to a lesser extent, enzyme replacement therapy have substantially altered the course of the disease. Furthermore, they have resulted in increased overall survival, especially for Hurler disease (MPS-1). However, despite the identification of clinical predictors and harmonized transplantation protocols, disease progression still poses a significant burden to patients, although at a slower pace. To design better therapies, we need to understand why and where current therapies fail. In this review, we discuss important aspects of the underlying disease and the disease progression. We note that the majority of progressive symptoms that occur in \u201chard-to-treat\u201d tissues are actually tissues that are difficult to reach, such as avascular connective tissue or tissues isolated from the circulation by a specific barrier (eg, blood-brain barrier, blood-retina barrier). Although easily reached tissues are effectively cured by HCT, disease progression is observed in these \u201chard-to-reach\u201d tissues. We used these insights to critically appraise ongoing experimental endeavors with regard to their potential to overcome the encountered hurdles and improve long-term clinical outcomes in MPS patients treated with HCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001708","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T15:39:45Z","timestamp":1592926785000},"page":"2837-2849","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Hurdles in treating Hurler disease: potential routes to achieve a \u201creal\u201d cure"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-0685","authenticated-orcid":false,"given":"Brigitte T. A.","family":"van den Broek","sequence":"first","affiliation":[{"name":"Sylvia Toth Center for Multidisciplinary Follow-up after Hematopoietic Cell Transplantation,"},{"name":"Pediatric Bone and Marrow Transplantation Program, and"},{"name":"Department of Pediatric Metabolic Diseases, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"van Doorn","sequence":"first","affiliation":[{"name":"Section of Metabolic Diagnostics, Department of Genetics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte V.","family":"Hegeman","sequence":"first","affiliation":[{"name":"Sylvia Toth Center for Multidisciplinary Follow-up after Hematopoietic Cell Transplantation,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-817X","authenticated-orcid":false,"given":"Stefan","family":"Nierkens","sequence":"first","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"},{"name":"Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Lindemans","sequence":"first","affiliation":[{"name":"Sylvia Toth Center for Multidisciplinary Follow-up after Hematopoietic Cell Transplantation,"},{"name":"Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanda","family":"Verhoeven-Duif","sequence":"first","affiliation":[{"name":"Section of Metabolic Diagnostics, Department of Genetics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"first","affiliation":[{"name":"Sylvia Toth Center for Multidisciplinary Follow-up after Hematopoietic Cell Transplantation,"},{"name":"Pediatric Blood and Marrow Transplantation Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"van Hasselt","sequence":"first","affiliation":[{"name":"Sylvia Toth Center for Multidisciplinary Follow-up after Hematopoietic Cell Transplantation,"},{"name":"Department of Pediatric Metabolic Diseases, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"issue":"3853","key":"2020062311393732000_B1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter Syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"2020062311393732000_B2","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"8249","key":"2020062311393732000_B3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","article-title":"Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation","volume":"2","author":"Hobbs","year":"1981","journal-title":"Lancet"},{"key":"2020062311393732000_B4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital J Pediatr"},{"issue":"5","key":"2020062311393732000_B5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/jimd.12103","article-title":"Limited data to evaluate real-world effectiveness of enzyme replacement therapy for mucopolysaccharidosis type I","volume":"42","author":"Kuiper","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2020062311393732000_B6","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","article-title":"Therapy for the mucopolysaccharidoses","volume":"50","author":"Valayannopoulos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2020062311393732000_B7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020062311393732000_B8","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-a ten-year report from the China Children Transplant Group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020062311393732000_B9","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/gim.2018.29","article-title":"Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison","volume":"20","author":"Eisengart","year":"2018","journal-title":"Genet Med"},{"issue":"19","key":"2020062311393732000_B10","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020062311393732000_B11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbmt.2009.01.020","article-title":"Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome","volume":"15","author":"Boelens","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020062311393732000_B12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1747-0285.2008.00741.x","article-title":"The structure of glycosaminoglycans and their interactions with proteins","volume":"72","author":"Gandhi","year":"2008","journal-title":"Chem Biol Drug Des"},{"issue":"2","key":"2020062311393732000_B13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/bj2520313","article-title":"Proteoglycan-fibrillar collagen interactions","volume":"252","author":"Scott","year":"1988","journal-title":"Biochem J"},{"key":"2020062311393732000_B14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-4613-0881-2_10","volume-title":"Cell Biology of Extracellular Matrix","author":"Toole","year":"1981"},{"issue":"2","key":"2020062311393732000_B15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1152\/physrev.1991.71.2.481","article-title":"Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes","volume":"71","author":"Jackson","year":"1991","journal-title":"Physiol Rev"},{"issue":"7","key":"2020062311393732000_B16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrm1681","article-title":"Heparan sulphate proteoglycans: the sweet side of development","volume":"6","author":"H\u00e4cker","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"2020062311393732000_B19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/glycob\/6.5.489","article-title":"Brain extracellular matrix","volume":"6","author":"Ruoslahti","year":"1996","journal-title":"Glycobiology"},{"issue":"4","key":"2020062311393732000_B20","doi-asserted-by":"crossref","first-page":"57R","DOI":"10.1093\/glycob\/12.4.57R","article-title":"Chondrodysplasias due to proteoglycan defects","volume":"12","author":"Schwartz","year":"2002","journal-title":"Glycobiology"},{"key":"2020062311393732000_B21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13052-018-0564-z","article-title":"New treatments for the mucopolysaccharidoses: from pathophysiology to therapy","volume":"44","author":"Fecarotta","year":"2018","journal-title":"Ital J Pediatr"},{"key":"2020062311393732000_B22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399408000550","article-title":"The mucopolysaccharidoses: a success of molecular medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"Expert Rev Mol Med"},{"issue":"11","key":"2020062311393732000_B23","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.bbadis.2011.07.013","article-title":"Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options","volume":"1812","author":"Oussoren","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2020062311393732000_B24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10545-011-9304-x","article-title":"Orthopaedic management of Hurler\u2019s disease after hematopoietic stem cell transplantation: a systematic review","volume":"34","author":"van der Linden","year":"2011","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"2020062311393732000_B25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2106\/JBJS.O.00601","article-title":"Progression of hip dysplasia in mucopolysaccharidosis type I Hurler after successful hematopoietic stem cell transplantation","volume":"98","author":"Langereis","year":"2016","journal-title":"J Bone Joint Surg Am"},{"issue":"13","key":"2020062311393732000_B26","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020062311393732000_B27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-011-9309-5","article-title":"The craniocervical junction following successful haematopoietic stem cell transplantation for mucopolysaccharidosis type I H (Hurler syndrome)","volume":"34","author":"Miebach","year":"2011","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"2020062311393732000_B28","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020062311393732000_B29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1089\/scd.2011.0555","article-title":"Hurler disease bone marrow stromal cells exhibit altered ability to support osteoclast formation","volume":"21","author":"Gatto","year":"2012","journal-title":"Stem Cells Dev"},{"issue":"1-2","key":"2020062311393732000_B30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/B:GLYC.0000043747.87325.5e","article-title":"Sulfation pattern in glycosaminoglycan: does it have a code?","volume":"21","author":"Habuchi","year":"2004","journal-title":"Glycoconj J"},{"issue":"5","key":"2020062311393732000_B31","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.2353\/ajpath.2009.090211","article-title":"Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities","volume":"175","author":"Wilson","year":"2009","journal-title":"Am J Pathol"},{"issue":"5","key":"2020062311393732000_B32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-0004.1998.tb02745.x","article-title":"Murine MPS I: insights into the pathogenesis of Hurler syndrome","volume":"53","author":"Russell","year":"1998","journal-title":"Clin Genet"},{"issue":"4","key":"2020062311393732000_B33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s13244-013-0246-8","article-title":"Imaging findings of mucopolysaccharidoses: a pictorial review","volume":"4","author":"Palmucci","year":"2013","journal-title":"Insights Imaging"},{"issue":"1","key":"2020062311393732000_B34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/157339709787315320","article-title":"Transport properties of cartilaginous tissues","volume":"5","author":"Jackson","year":"2009","journal-title":"Curr Rheumatol Rev"},{"key":"2020062311393732000_B35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2016.01.029","article-title":"Altered interaction and distribution of glycosaminoglycans and growth factors in mucopolysaccharidosis type I bone disease","volume":"88","author":"Kingma","year":"2016","journal-title":"Bone"},{"issue":"67","key":"2020062311393732000_B36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/bjs.1800176705","article-title":"Congenital dislocation of the hip: with special reference to the anatomy","volume":"17","author":"Fairbank","year":"1930","journal-title":"Br J Surg"},{"issue":"6","key":"2020062311393732000_B37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01241398-199611000-00006","article-title":"Hip dysplasia in Hurler\u2019s syndrome: orthopaedic management after bone marrow transplantation","volume":"16","author":"Masterson","year":"1996","journal-title":"J Pediatr Orthop"},{"issue":"22","key":"2020062311393732000_B38","first-page":"3956","article-title":"Lower-limb valgus deformity associated with developmental hip dysplasia","volume":"125","author":"Guo","year":"2012","journal-title":"Chin Med J (Engl)"},{"issue":"160","key":"2020062311393732000_B39","first-page":"14","article-title":"Patterns of deformity of the developing hip","author":"Siffert","year":"1981","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"2020062311393732000_B40","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.joca.2013.08.001","article-title":"Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation","volume":"21","author":"Opoka-Winiarska","year":"2013","journal-title":"Osteoarthritis Cartilage"},{"issue":"11","key":"2020062311393732000_B41","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/ard.2008.095315","article-title":"Musculoskeletal manifestations of lysosomal storage disorders","volume":"68","author":"Aldenhoven","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2020062311393732000_B42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.bor.0000147283.40529.13","article-title":"Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I)","volume":"17","author":"Pastores","year":"2005","journal-title":"Curr Opin Rheumatol"},{"issue":"suppl 5","key":"2020062311393732000_B43","doi-asserted-by":"crossref","first-page":"v19","DOI":"10.1093\/rheumatology\/ker397","article-title":"Musculoskeletal manifestations of mucopolysaccharidoses","volume":"50","author":"Morishita","year":"2011","journal-title":"Rheumatology"},{"issue":"5","key":"2020062311393732000_B44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","article-title":"The clinical outcome of Hurler syndrome after stem cell transplantation","volume":"14","author":"Aldenhoven","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020062311393732000_B45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01241398-200401000-00019","article-title":"Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation","volume":"24","author":"Weisstein","year":"2004","journal-title":"J Pediatr Orthop"},{"issue":"12","key":"2020062311393732000_B46","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/sj.bmt.1704105","article-title":"Outcome of 27 patients with Hurler\u2019s syndrome transplanted from either related or unrelated haematopoietic stem cell sources","volume":"31","author":"Souillet","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020062311393732000_B47","first-page":"677","article-title":"Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I","volume":"134","author":"Breider","year":"1989","journal-title":"Am J Pathol"},{"issue":"Pt 3","key":"2020062311393732000_B48","first-page":"503","article-title":"The joint capsule: structure, composition, ageing and disease","volume":"184","author":"Ralphs","year":"1994","journal-title":"J Anat"},{"issue":"1","key":"2020062311393732000_B49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13023-019-0997-5","article-title":"Treatment of thoracolumbar kyphosis in patients with mucopolysaccharidosis type I: results of an international consensus procedure","volume":"14","author":"Kuiper","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2020062311393732000_B50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13052-018-0554-1","article-title":"Anesthesiological risks in mucopolysaccharidoses","volume":"44","author":"Moretto","year":"2018","journal-title":"Ital J Pediatr"},{"issue":"3","key":"2020062311393732000_B51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0883073807300528","article-title":"Carpal tunnel syndrome in children with mucopolysaccaridoses","volume":"22","author":"Yuen","year":"2007","journal-title":"J Child Neurol"},{"issue":"2","key":"2020062311393732000_B52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/1753193414523356","article-title":"Objective results of median nerve decompression and tenosynovectomy for carpal tunnel syndrome in patients with mucopolysaccharidoses types I and II","volume":"40","author":"Aslam","year":"2015","journal-title":"J Hand Surg Eur Vol"},{"issue":"2","key":"2020062311393732000_B53","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0363-5023(98)80120-2","article-title":"Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders","volume":"23","author":"Van Heest","year":"1998","journal-title":"J Hand Surg Am"},{"issue":"12","key":"2020062311393732000_B54","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/dmcn.13545","article-title":"Carpal tunnel syndrome in mucopolysaccharidosis I: a registry-based cohort study","volume":"59","author":"Viskochil","year":"2017","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"2020062311393732000_B55","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0161-6420(98)96014-6","article-title":"Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up","volume":"105","author":"Gullingsrud","year":"1998","journal-title":"Ophthalmology"},{"key":"2020062311393732000_B56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1442-9071.2010.02366.x","article-title":"Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy\u2013a review","volume":"38","author":"Summers","year":"2010","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"2020062311393732000_B57","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bbmt.2019.11.025","article-title":"Longitudinal analysis of ocular disease in children with mucopolysaccharidosis I after hematopoietic cell transplantation","volume":"26","author":"van den Broek","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020062311393732000_B58","first-page":"531","article-title":"Corneal manifestations of the systemic mucopolysaccharidoses","volume":"11","author":"Sugar","year":"1979","journal-title":"Ann Ophthalmol"},{"issue":"5","key":"2020062311393732000_B59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1006\/exer.1998.0622","article-title":"Altered corneal stromal matrix organization is associated with mucopolysaccharidosis I, III and VI","volume":"68","author":"Alroy","year":"1999","journal-title":"Exp Eye Res"},{"issue":"7","key":"2020062311393732000_B60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1755-3768.2011.02280.x","article-title":"Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidosis","volume":"90","author":"Fahnehjelm","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"2020062311393732000_B61","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0002-9149(03)00909-3","article-title":"Usefulness of bone marrow transplantation in the Hurler syndrome","volume":"92","author":"Braunlin","year":"2003","journal-title":"Am J Cardiol"},{"key":"2020062311393732000_B62","first-page":"462a","article-title":"Echocardiographic follow-up of Hurler syndrome after bone marrow transplantation","volume":"84","author":"Stauffer","year":"1991","journal-title":"Circulation"},{"issue":"1","key":"2020062311393732000_B63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-physiol-012110-142145","article-title":"Heart valve structure and function in development and disease","volume":"73","author":"Hinton","year":"2011","journal-title":"Annu Rev Physiol"},{"key":"2020062311393732000_B64","doi-asserted-by":"crossref","first-page":"979351","DOI":"10.1155\/2012\/979351","article-title":"Fine structure of glycosaminoglycans from fresh and decellularized porcine cardiac valves and pericardium","volume":"2012","author":"Cigliano","year":"2012","journal-title":"Biochem Res Int"},{"issue":"5","key":"2020062311393732000_B65","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1067\/mtc.2001.117621","article-title":"Mechanical properties of myxomatous mitral valves","volume":"122","author":"Barber","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"2020062311393732000_B66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0735-1097(03)00626-0","article-title":"Glycosaminoglycan profiles of myxomatous mitral leaflets and chordae parallel the severity of mechanical alterations","volume":"42","author":"Grande-Allen","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"2020062311393732000_B67","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1161\/CIRCULATIONAHA.108.805911","article-title":"Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering","volume":"118","author":"Schoen","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"2020062311393732000_B68","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1167\/iovs.08-1738","article-title":"Characteristics of bone marrow-derived microglia in the normal and injured retina","volume":"49","author":"Kaneko","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2020062311393732000_B69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/8904_2014_350","article-title":"Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III","volume":"18","author":"Welling","year":"2015","journal-title":"JIMD Rep"},{"key":"2020062311393732000_B70","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122S","author":"Scarpa","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"2","key":"2020062311393732000_B71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ymgme.2012.03.022","article-title":"Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII","volume":"106","author":"Macsai","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2020062311393732000_B72","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/hum.2014.158","article-title":"Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II","volume":"26","author":"Wakabayashi","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2020062311393732000_B73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymgme.2016.09.003","article-title":"Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy","volume":"119","author":"Derrick-Roberts","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"5","key":"2020062311393732000_B74","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic stem cell gene therapy for storage disease: current and new indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol Ther"},{"issue":"2","key":"2020062311393732000_B75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ymgme.2014.09.011","article-title":"Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier","volume":"114","author":"Aronovich","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"7","key":"2020062311393732000_B76","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/mt.2009.87","article-title":"Systemic correction of storage disease in MPS I NOD\/SCID mice using the sleeping beauty transposon system","volume":"17","author":"Aronovich","year":"2009","journal-title":"Mol Ther"},{"issue":"4","key":"2020062311393732000_B77","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymgme.2007.04.009","article-title":"Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI","volume":"91","author":"Auclair","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2020062311393732000_B78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/PRM-2010-0101","article-title":"An overview of intra-articular therapy for mucopolysaccharidosis VI","volume":"3","author":"Auclair","year":"2010","journal-title":"J Pediatr Rehabil Med"},{"issue":"4","key":"2020062311393732000_B79","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2014.05.015","article-title":"Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I","volume":"112","author":"Wang","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2020062311393732000_B80","doi-asserted-by":"crossref","first-page":"22131","DOI":"10.1038\/srep22131","article-title":"AAV gene therapy for MPS1-associated corneal blindness","volume":"6","author":"Vance","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"2020062311393732000_B81","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2017.187","article-title":"Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I","volume":"28","author":"Belur","year":"2017","journal-title":"Hum Gene Ther"},{"key":"2020062311393732000_B82","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2020062311393732000_B83","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1089\/hum.2019.012","article-title":"Safe and sustained expression of human iduronidase after intrathecal administration of adeno-associated virus serotype 9 in infant rhesus monkeys","volume":"30","author":"Hordeaux","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2020062311393732000_B84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"8","key":"2020062311393732000_B85","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"2020062311393732000_B86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1423-0127-16-26","article-title":"Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway","volume":"16","author":"Jak\u00f3bkiewicz-Banecka","year":"2009","journal-title":"J Biomed Sci"},{"issue":"3","key":"2020062311393732000_B87","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/01.pdr.0000233037.00707.da","article-title":"Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA","volume":"60","author":"Roberts","year":"2006","journal-title":"Pediatr Res"},{"issue":"1","key":"2020062311393732000_B88","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3390\/diseases5010005","article-title":"Substrate deprivation therapy to reduce glycosaminoglycan synthesis improves aspects of neurological and skeletal pathology in MPS I mice","volume":"5","author":"Derrick-Roberts","year":"2017","journal-title":"Diseases"},{"issue":"4","key":"2020062311393732000_B89","doi-asserted-by":"crossref","first-page":"CR196","DOI":"10.12659\/MSM.881715","article-title":"Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients","volume":"17","author":"Piotrowska","year":"2011","journal-title":"Med Sci Monit"},{"issue":"9","key":"2020062311393732000_B90","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)","volume":"155A","author":"Marucha","year":"2011","journal-title":"Am J Med Genet A"},{"issue":"5","key":"2020062311393732000_B91","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/21678707.2013.780970","article-title":"Emerging therapies and therapeutic concepts for lysosomal storage diseases","volume":"1","author":"Kirkegaard","year":"2013","journal-title":"Expert Opin Orphan Drugs"},{"issue":"99","key":"2020062311393732000_B92","first-page":"S12","article-title":"22. Small molecule inhibitors of glycosaminoglycan biosynthesis as substrate optimization therapy for the mucopolysaccharidoses","volume":"2","author":"Brown","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"10","key":"2020062311393732000_B93","doi-asserted-by":"crossref","first-page":"e7434","DOI":"10.1371\/journal.pone.0007434","article-title":"Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C","volume":"4","author":"Feldhammer","year":"2009","journal-title":"PLoS One"},{"issue":"9","key":"2020062311393732000_B94","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dnp.2008.21.9.1290820","article-title":"A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery","volume":"21","author":"Boado","year":"2008","journal-title":"Drug News Perspect"},{"issue":"1","key":"2020062311393732000_B95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/mp900235k","article-title":"Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor","volume":"7","author":"Boado","year":"2010","journal-title":"Mol Pharm"},{"issue":"4","key":"2020062311393732000_B96","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","article-title":"Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein","volume":"14","author":"Boado","year":"2017","journal-title":"Mol Pharm"},{"key":"2020062311393732000_B97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mcn.2016.08.009","article-title":"Transferrin receptor expression and role in transendothelial transport of transferrin in cultured brain endothelial monolayers","volume":"76","author":"Hersom","year":"2016","journal-title":"Mol Cell Neurosci"},{"issue":"9","key":"2020062311393732000_B98","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1523\/JNEUROSCI.4785-13.2014","article-title":"Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A","volume":"34","author":"B\u00f6ckenhoff","year":"2014","journal-title":"J Neurosci"},{"issue":"8","key":"2020062311393732000_B99","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.1222742110","article-title":"Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier","volume":"110","author":"Wang","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2020062311393732000_B100","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1038\/mt.2014.152","article-title":"Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase","volume":"22","author":"El-Amouri","year":"2014","journal-title":"Mol Ther"},{"key":"2020062311393732000_B101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","journal-title":"Bone Rep"},{"issue":"12","key":"2020062311393732000_B102","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/17425247.2016.1202235","article-title":"Nanotechnology applied to treatment of mucopolysaccharidoses","volume":"13","author":"Schuh","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"2020062311393732000_B103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ymgme.2014.12.001","article-title":"Therapies for the bone in mucopolysaccharidoses","volume":"114","author":"Tomatsu","year":"2015","journal-title":"Mol Genet Metab"},{"issue":"3","key":"2020062311393732000_B104","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jbm.a.34002","article-title":"Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases","volume":"100","author":"Wang","year":"2012","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"2020062311393732000_B105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijpharm.2018.06.049","article-title":"Intra-articular nonviral gene therapy in mucopolysaccharidosis I mice","volume":"548","author":"Bidone","year":"2018","journal-title":"Int J Pharm"},{"key":"2020062311393732000_B106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"5411","author":"Pittenger","year":"1999","journal-title":"Science"},{"issue":"6893","key":"2020062311393732000_B107","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature00870","article-title":"Pluripotency of mesenchymal stem cells derived from adult marrow [published correction appears in Nature. 2007;447(7146):879-880]","volume":"418","author":"Jiang","year":"2002","journal-title":"Nature"},{"issue":"6","key":"2020062311393732000_B108","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14653240310003611","article-title":"Immunomodulatory effects of fetal and adult mesenchymal stem cells","volume":"5","author":"Le Blanc","year":"2003","journal-title":"Cytotherapy"},{"issue":"3","key":"2020062311393732000_B109","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","article-title":"Mesenchymal stem cell homing: the devil is in the details","volume":"4","author":"Karp","year":"2009","journal-title":"Cell Stem Cell"},{"key":"2020062311393732000_B110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41409-019-0616-z","article-title":"Mesenchymal stem cell-derived exosomes for clinical use","volume":"54","author":"Mendt","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020062311393732000_B111","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/cells8040307","article-title":"Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes","volume":"8","author":"Gurunathan","year":"2019","journal-title":"Cells"},{"issue":"5","key":"2020062311393732000_B112","doi-asserted-by":"crossref","first-page":"e12807","DOI":"10.1111\/sji.12807","article-title":"Role of exosomes in tumour and transplant immune regulation","volume":"90","author":"Lema","year":"2019","journal-title":"Scand J Immunol"},{"issue":"3","key":"2020062311393732000_B113","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.07.012","article-title":"A shortcut to the lysosome: the mannose-6-phosphate-independent pathway","volume":"107","author":"Coutinho","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"10","key":"2020062311393732000_B114","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/stem.1481","article-title":"Transplantation of human umbilical mesenchymal stem cells cures the corneal defects of mucopolysaccharidosis VII mice","volume":"31","author":"Coulson-Thomas","year":"2013","journal-title":"Stem Cells"},{"issue":"11","key":"2020062311393732000_B115","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLI.0b013e3181e6f42f","article-title":"Optimal enhancement configuration of silica nanoparticles for ultrasound imaging and automatic detection at conventional diagnostic frequencies","volume":"45","author":"Casciaro","year":"2010","journal-title":"Invest Radiol"},{"key":"2020062311393732000_B116","article-title":"Treatment of ultrasound contrast agents for gene or drug delivery","volume":"4","author":"Wang","year":"2006","journal-title":"Zhongguo Jieru Yingxiang Yu Zhiliaoxue"},{"issue":"1","key":"2020062311393732000_B117","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/scipharm87010006","article-title":"Overcoming the blood-brain barrier. Challenges and tricks for CNS drug delivery","volume":"87","author":"Bors","year":"2019","journal-title":"Sci Pharm"},{"issue":"4","key":"2020062311393732000_B118","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1021\/cn300191b","article-title":"Noninvasive and targeted drug delivery to the brain using focused ultrasound","volume":"4","author":"Burgess","year":"2013","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"2020062311393732000_B119","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3171\/2016.3.JNS151635","article-title":"Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model","volume":"126","author":"Horodyckid","year":"2017","journal-title":"J Neurosurg"},{"issue":"1","key":"2020062311393732000_B120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-017-0649-6","article-title":"Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for mucopolysaccharidosis type I disease","volume":"12","author":"Hsu","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2020062311393732000_B121","doi-asserted-by":"crossref","first-page":"e42754","DOI":"10.1371\/journal.pone.0042754","article-title":"Targeted and reversible blood-retinal barrier disruption via focused ultrasound and microbubbles","volume":"7","author":"Park","year":"2012","journal-title":"PLoS One"},{"key":"2020062311393732000_B122","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front Pediatr"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2837\/1745768\/advancesadv2020001708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2837\/1745768\/advancesadv2020001708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T15:41:00Z","timestamp":1592926860000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/12\/2837\/461072\/Hurdles-in-treating-Hurler-disease-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":120,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001708","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}